Treatment with CNX-013-B2 ameliorated macrovescicular steatosis in liver (Figure 5D H&E), reduced muscle triglyceride content (Additional file 2D) and also reduced adipose hypertrophy (Figure 4B and C), thus leading to improvement in insulin sensitivity [53]. This evidence concerns the gene INS and steatosis.